PTEN and neoplasm: In summary, these findings suggest that PTEN deletion enhances tumor resistance to ICB and supports the idea that ICB combined with PI3K-AKT pathway inhibitors may benefit cancer patients bearing PTEN deletion (Peng et al., 2016).